로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > LAG-3

LAG-3

요약

Name:Lymphocyte activation gene 3 protein
Target Synonym:Lymphocyte activation gene 3 protein,LAG3,Lymphocyte Activating 3,Lymphocyte-Activation Gene 3,CD223 Antigen,Protein FDC,CD223,LAG-3,FDC,sLAG-3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:25
Lastest Research Phase:Approved

라이센싱

항목 적응증 연구 단계 합작 수요
BMA202203 Advanced solid tumors Phase 1 License-out or co-development
BMS21011 Tumors such as melanoma, non-small cell lung cancer,liver cancer, gastric carcinoma Cell line screening Project authorization, transfer or co-development. (project’s company is seeking for external cooperation to accelate drug research and development.)

제품 리스트 비교 또는 구매

제품번호 제품 설명 구조 순도 특징
LA3-H82E9 Human Biotinylated Human LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-H82E9-structure
LA3-H82E9-sds
LA3-C8258 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, ultra sensitivity (primary amine labeling)
LA3-C8258-structure
LA3-C8258-sds
LA3-C52H7 Canine Canine LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-C52H7-structure
LA3-C52H7-sds
LA3-C82H3 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, His Tag
LA3-C82H3-structure
LA3-C82H3-sds
LA3-C82E5 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, His,Avitag™
LA3-C82E5-structure
LA3-C82E5-sds
LA3-M82E5 Mouse Biotinylated Mouse LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-M82E5-structure
LA3-M82E5-sds
LA3-H82Fb Human Biotinylated Human LAG-3 / CD223 Protein, Fc,Avitag™ (MALS verified)
LA3-H82Fb-structure
LA3-H82Fb-sds
LA3-H525c Human Human LAG-3 / CD223 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
LA3-H525c-structure
LA3-H525c-sds
LA3-H522a Human Human LAG-3 / CD223 Protein, His Tag, low endotoxin
LA3-H522a-structure
LA3-H522a-sds
LA3-H82F3 Human Biotinylated Human LAG-3 / CD223 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
LA3-H82F3-structure
LA3-H82F3-sds
LA3-M52Ha Marmoset Marmoset LAG-3 / CD223 Protein, His Tag
LA3-M52Ha-structure
LA3-M52Ha-sds
LA3-H52Aa Human Human LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag (MALS verified)
LA3-H52Aa-structure
LA3-H52Aa-sds
LA3-C52A0 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag
LA3-C52A0-structure
LA3-C52A0-sds
LA3-C5252 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Fc Tag
LA3-C5252-structure
LA3-C5252-sds
LA3-H5255 Human Human LAG3 / CD223 Protein, Fc Tag (MALS Verified)
LA3-H5255-structure
LA3-H5255-sds
LA3-M52H5 Mouse Mouse LAG-3 / CD223 Protein, His Tag
LA3-M52H5-structure
LA3-M52H5-sds
LA3-R52H5 Rat Rat LAG3 / CD223 Protein, His Tag
LA3-R52H5-structure
LA3-R52H5-sds
LA3-H5222 Human Human LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-H5222-structure
LA3-H5222-sds

일부의 생물활성 데이터

LA3-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human LAG-3, Mouse IgG2a Fc,Avitag (Cat. No. LA3-H82F3) can bind to daudi cell surface. The concentration of LAG-3 used is 0.3 μg/mL (Routinely tested).

LA3-H52Aa-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Human LAG3, Mouse IgG2a Fc Tag (Cat. No. LA3-H52Aa) can bind to daudi cell surface. The concentration of LAG3 used is 0.3 μg/mL (Routinely tested).

LA3-H5222-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-LAG-3 MAb (Human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 4.57 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

LA3-H5222-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Anti-LAG-3 MAb (Human IgG1) on AHC Biosensor, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 7.47 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

사용자 리뷰

Synonym Name

LAG3,CD223,FDC

Background

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Approved Bristol-Myers Squibb Company OPDUALAG United States Melanoma Bristol-Myers Squibb Company 2022-03-18 Solid tumours; Melanoma Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Anti-LAG3 antibody (Gloria) Phase 1 Clinical Harbin Gloria Pharmaceuticals Co Ltd Solid tumours; Neoplasms Details
KL-A289 KL-A289 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Solid tumours Details
Encelimab TSR-033; TSR 033; TSR033; GSK-4074386 Anaptysbio Inc Details
IBI-323(Innovent Biologics) IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
EMB-02 EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
Miptenalimab BI-754111 C.H. Boehringer Sohn Ag & Co. Kg Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Neoplasm Metastasis Details
Sym-022 Sym-022 Symphogen Details
Mavezelimab MK-4280 Merck Sharp & Dohme Corp Details
Bavunalimab XmAb-22841; XmAb-841 Xencor Details
GSK-2831781 IMP-731; GSK‘-781; GSK-2831781; ImmuTune-IMP731 Prima Biomed Details
SHR-1802 SHR-1802 Phase 2 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Solid tumours Details
HLX-26 HLX-26 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Lymphoma Details
Mavezelimab/Pembrolizumab MK-4280A Phase 3 Clinical Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms Details
FS 118 FS-118 Phase 2 Clinical Merck Serono, F-Star Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis Details
Ieramilimab IMP-701; LAG-525 Phase 2 Clinical Immutep Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Esophageal adenocarcinoma; Melanoma; Persistent Fetal Circulation Syndrome Details
Fianlimab REGN-3767 Phase 3 Clinical Regeneron Pharmaceuticals Inc Melanoma Details
IBI-110 IBI-110 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung Details
INCAGN-2385 INCAGN-2385; INCAGN-02385 Phase 2 Clinical Agenus Inc Head and Neck Neoplasms; Melanoma Details
MIL-98 MIL-98 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours; Breast Neoplasms; Lymphoma; Melanoma Details
Relatlimab ONO-4482; BMS-986016 Phase 3 Clinical Bristol-Myers Squibb Company Chordoma; Adenocarcinoma; Carcinoma, Hepatocellular; Large intestine neoplasm; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Gliosarcoma; Colorectal Neoplasms; Sarcoma; Brain Neoplasms; Solid tumours; Multiple Myeloma; Uveal melanoma; Microsatellite instability-high cancer; Hodgkin Disease; Glioblastoma; Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Hematologic Neoplasms Details
LBL-007 LBL-007 Phase 2 Clinical Leads Biolabs Inc, Nanjing Leads Biolabs Co Ltd Solid tumours; Neoplasms; Lymphoma; Melanoma Details
Eftilagimod alpha hLAG-3Ig; CD-223; EDP-202; EOC-202; IMP-321 Phase 2 Clinical Immutep, Prima Biomed Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
RO-7247669 RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Liver Neoplasms; Solid tumours; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
DNV-3 DNV3; DNV-3 Phase 2 Clinical Zhejiang Shimai Pharmaceutical Co Ltd Solid tumours; Neoplasms; Lymphoma Details

This web search service is supported by Google Inc.

totop